CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Imidazole antifungal
Updated · Methodology
Mechanism
Miconazole from the oral gel reaches the bloodstream, and its summary of product characteristics (SmPC) describes it as a clinically potent CYP3A4 inhibitor. It can therefore raise the levels of drugs that this enzyme metabolises and increase or prolong their effects and adverse effects (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The gel SmPC names cisapride among QT-prolonging drugs that CYP3A4 metabolises. Higher levels of these drugs can prolong the QT interval and cause potentially fatal torsade de pointes (miconazole oral gel SmPC, AEMPS). The miconazole documents give no study figures for this pair. After a 60 mg dose of gel, plasma miconazole peaks at 31–49 ng/mL after about 2 hours, and the half-life is 20–25 hours in most patients (miconazole oral gel SmPC, AEMPS). Less than 1% of a cream dose is absorbed (miconazole cream SmPC, AEMPS). Each Spanish vaginal ovule contains 100 mg of miconazole with 300 mg of metronidazole. Their SmPC gives data for 1200 mg miconazole ovules: a peak plasma level of about 10–12 ng/mL, more than 100 times lower than after oral or intravenous use (vaginal ovule SmPC, AEMPS).
Symptoms
According to the miconazole oral gel summary of product characteristics (SmPC), higher levels of QT-prolonging drugs can prolong the QT interval and cause potentially fatal torsade de pointes (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. Heart rhythm disorders are not among the adverse reactions of the gel itself. The danger of the combination comes from higher cisapride levels (miconazole oral gel SmPC, AEMPS).
Management
The combination is contraindicated for oral miconazole. The miconazole oral gel summary of product characteristics (SmPC) contraindicates miconazole with cisapride and names cisapride among QT-prolonging drugs that the enzyme CYP3A4 metabolises (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Patients hold the gel in the mouth and then swallow it, so the contraindication also applies when it is used for oral or oesophageal candidiasis (miconazole oral gel SmPC, AEMPS). Cisapride is not in the Spanish medicines register CIMA, so the miconazole documents set the level of risk. If a person takes cisapride obtained in another country, do not prescribe miconazole oral gel with it (miconazole oral gel SmPC, AEMPS). No document states how long to wait after stopping the gel before starting cisapride. The half-life of miconazole is 20–25 hours in most patients (miconazole oral gel SmPC, AEMPS). The US label for miconazole buccal tablets does not name cisapride, but states that interactions with drugs metabolised by CYP3A4 cannot be ruled out, although little miconazole reaches the blood (miconazole label, US Food and Drug Administration, FDA). The miconazole cream SmPC mentions neither cisapride nor QT-prolonging drugs. According to it, little miconazole reaches the blood and clinically relevant interactions are rare (miconazole cream SmPC, AEMPS). The vaginal ovules also contain metronidazole, and 20–25% of it is absorbed from the ovule. Their SmPC has a separate line: QT prolongation has been reported, particularly when metronidazole was given with QT-prolonging drugs (vaginal ovule SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Daktarin 20 mg/g gel oral, miconazol (nº registro 55962), sección 4.3 (2026)– AEMPS, CIMA, nº registro 55962 (Daktarin 20 mg/g gel oral, JNTL Consumer Health), revisión 06/2026, secciones 4.3, 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Blasgina óvulos vaginales (nº registro 50441), sección 4.5 (2026)– AEMPS, CIMA, nº registro 50441 (Blasgina óvulos vaginales, Almirall), revisión 09/2026, secciones 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Miconazol crema (nº registro 50271), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 50271 (Daktarin 20 mg/g crema), revisión 06/2026, secciones 4.4, 4.5 y 5.2 (en el HTML de CIMA siguen al apartado 4.3, sin ancla propia)
- FDA: ORAVIG (miconazole) buccal tablets prescribing information (2026)– FDA, DailyMed setid dc2427ff-e566-4b48-b289-9e51c011250a, Galt Pharmaceuticals, revisión 01/2026 (versión 3), secciones 7.1, 7.2 y 12.3
- AEMPS: Ficha técnica: Daktarin 20 mg/g gel oral, miconazol (nº registro 55962), sección 4.5 (2026)– AEMPS, CIMA, nº registro 55962 (Daktarin 20 mg/g gel oral, JNTL Consumer Health), revisión 06/2026 (texto revisado 08/2025), secciones 4.2, 4.4, 4.5 y 5.2